Global Overactive Bladder Therapeutics Market 2014-2018

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Enablex/Emselex
04.1.2 Gelnique
04.1.3 Oxytrol
04.1.4 Botox
04.1.5 Sanctura/ Sanctura XR
04.1.6 Myrbetriq
04.1.7 Vesicare
04.1.8 Detrol/Detrol LA
04.1.9 Toviaz
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Molecule Type
08.1 Biologics
08.2 Small Molecules
09. Market Segmentation by Route of Administration
09.1 Oral
09.2 Parenteral
09.3 Topical
10. Market Segmentation by Class of drugs
10.1 Anti-muscarinic Agent
10.2 Beta-3-Adrenergic Receptor Agonist
11. Market Segmentation by Dosage Form
11.1 Solid
11.2 Liquid
11.3 Semisolid
11.4 Transdermal
12. Rate of Incidence and Prevalence
13. Geographical Segmentation
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2013
21.2.1 Actavis
21.2.2 Allergan
21.2.3 Astellas Pharma
21.2.4 Pfizer
21.3 Other and Future Prominent Vendors
22. Pipeline Portfolio
23. Key Vendor Analysis
23.1 Actavis plc
23.1.1 Key Facts
23.1.2 Business Description
23.1.3 Business Segmentation
23.1.4 Business Segmentation by Revenue 2012 and 2013
23.1.5 Sales by Geography
23.1.6 Business Strategy
23.1.7 Key Information
23.1.8 SWOT Analysis
23.2 Allergan Inc.
23.2.1 Key Facts
23.2.2 Business Description
23.2.3 Business Segmentation
23.2.4 Revenue by Business Segmentation
23.2.5 Revenue Comparison 2011-2013
23.2.6 Revenue by Geographical Segmentation
23.2.7 Business Strategy
23.2.8 Key Developments
23.2.9 SWOT Analysis
23.3 Astellas Pharma
23.3.1 Key Facts
23.3.2 Business Overview
23.3.3 Product Segmentation
23.3.4 Product Segmentation by Revenue 2012 and 2013
23.3.5 Geographical Segmentation by Revenue 2013
23.3.6 Business Strategy
23.3.7 Recent Developments
23.3.8 SWOT Analysis
23.4 Pfizer
23.4.1 Key Facts
23.4.2 Business Overview
23.4.3 Business Segmentation by Revenue 2013
23.4.4 Business Segmentation by Revenue 2012 and 2013
23.4.5 Geographical Segmentation by Revenue
23.4.6 Business Strategy
23.4.7 Key Developments
23.4.8 SWOT Analysis
24. Other Reports in this Series

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

• Manufacturers and suppliers
• Channel partners
• Industry experts
• Strategic decision makers

Secondary sources

• Industry journals and periodicals
• Government data
• Financial reports of key industry players
• Historical data
• Press releases

DATA ANALYSIS

Data Synthesis

• Collation of data
• Estimation of key figures
• Analysis of derived insights

Data Validation

• Triangulation with data models
• Reference against proprietary databases
• Corroboration with industry experts

REPORT WRITING